<?xml version="1.0" encoding="UTF-8"?>
<!--Inline XBRL document created by Certent CDM HD version: 21.3.5 -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:vaxx="http://www.vaxxinity.com/20220324" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" version="-//XBRL International//DTD XHTML Inline XBRL 1.1//EN" xml:lang="en-US">
<head><title>20220317_8k</title>
<meta http-equiv="Content-Type" content="text/html;" />
</head>
<body style="background-color:RGB(230, 230, 230);font-family:Times New Roman;font-style:normal;font-size:13.28px;font-weight:normal;font-stretch:normal;color:#000000;">
<div style="display:none;">
<ix:header>
<ix:hidden>
<ix:nonNumeric id="ID_22" name="dei:AmendmentFlag" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657">false</ix:nonNumeric>
<ix:nonNumeric id="ID_23" name="dei:EntityCentralIndexKey" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657">0001851657</ix:nonNumeric>
<ix:nonNumeric id="ID_20" name="dei:SecurityExchangeName" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657">NASDAQ</ix:nonNumeric>
</ix:hidden>
<ix:references xml:lang="en-US"><link:schemaRef xlink:href="vaxx-20220324.xsd" xlink:type="simple" /></ix:references>
<ix:resources>

  <xbrli:context id="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657">

    <xbrli:entity>

      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001851657</xbrli:identifier>

    </xbrli:entity>

    <xbrli:period>

      <xbrli:startDate>2022-03-24</xbrli:startDate>

      <xbrli:endDate>2022-03-24</xbrli:endDate>

    </xbrli:period>

  </xbrli:context>
</ix:resources>
</ix:header>
</div>
<div id="fixed-layout-inline-document" style="display:none;"></div><div id="Doc1" style="background-color:RGB(230, 230, 230);line-height:normal;font-family:Times New Roman;font-size:13.28px;font-weight:400;">
<div style="padding: 7px">
<div id="Page1" style="background-color:RGB(255, 255, 255);position:relative;margin-left:auto;margin-right:auto;overflow:hidden;border-style:solid;border-width:thin;border-color:RGB(198, 198, 198);page-break-after:always;width:816px;height:1056px;">
<div style="position:absolute; width:244.9px; height:1.3px; left:48px; top:815px; background-color:#000000; ">&#160;</div>
<div style="position:absolute; width:230.4px; height:1.3px; left:300.1px; top:815px; background-color:#000000; ">&#160;</div>
<div style="position:absolute; width:230.4px; height:1.3px; left:537.7px; top:815px; background-color:#000000; ">&#160;</div>
<div id="a1" style="position:absolute;font-family:'Times New Roman';font-size:24px;font-weight:bold;left:312px;top:49px;">UNITED STATES</div><div id="a3" style="position:absolute;font-family:'Times New Roman';font-size:24px;font-weight:bold;left:150px;top:76px;">SECURITIES AND EXCHANGE COMMISSION </div><div id="a6" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:339px;top:122px;">Washington, D.C. 20549 </div><div id="a8" style="position:absolute;font-family:'Times New Roman';font-size:16px;left:288px;top:137px;">______________________________ </div><div id="a10" style="position:absolute;font-family:'Times New Roman';font-size:24px;font-weight:bold;left:349px;top:156px;">FORM </div><div id="a10_5_3" style="position:absolute;font-family:'Times New Roman';font-size:24px;font-weight:bold;left:429px;top:156px;"><ix:nonNumeric id="ID_0" name="dei:DocumentType" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657">8-K</ix:nonNumeric></div><div id="a14" style="position:absolute;font-family:'Times New Roman';left:288px;top:183px;">____________________________________</div><div id="a16" style="position:absolute;font-family:'Times New Roman';font-size:16px;font-weight:bold;left:333px;top:199px;">CURRENT REPORT</div><div id="a20" style="position:absolute;font-family:'Times New Roman';font-size:16px;font-weight:bold;left:269px;top:232px;">PURSUANT TO SECTION 13 OR 15(d)<div style="display:inline-block;width:4px">&#160;</div></div><div id="a26" style="position:absolute;font-family:'Times New Roman';font-size:16px;font-weight:bold;left:229px;top:251px;">OF THE SECURITIES EXCHANGE ACT OF 1934</div><div id="a30" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:95px;top:288px;">Date of Report (Date of earliest event reported):</div><div id="a38" style="position:absolute;font-family:'Times New Roman';font-size:1.28px;font-weight:bold;left:415px;top:304px;"><div style="display:inline-block;width:0px">&#160;</div></div><div id="a40" style="position:absolute;font-family:'Times New Roman';font-size:16px;font-weight:bold;left:557px;top:288px;"><ix:nonNumeric id="ID_1" name="dei:DocumentPeriodEndDate" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657" format="ixt:datemonthdayyearen">March 24, 2022</ix:nonNumeric></div><div id="a43" style="position:absolute;font-family:'Times New Roman';left:288px;top:306px;">____________________________________</div><div id="a47" style="position:absolute;font-family:'Times New Roman';font-size:24px;font-weight:bold;left:332px;top:337px;"><ix:nonNumeric id="ID_2" name="dei:EntityRegistrantName" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657">Vaxxinity, Inc.</ix:nonNumeric></div><div id="a49" style="position:absolute;font-family:'Times New Roman';left:270px;top:364px;">(Exact name of registrant as specified in its charter)</div><div id="a51" style="position:absolute;font-family:'Times New Roman';left:288px;top:380px;">____________________________________</div><div id="a59" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:141px;top:410px;"><ix:nonNumeric id="ID_3" name="dei:EntityIncorporationStateCountryCode" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></div><div id="a61" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:376px;top:410px;"><ix:nonNumeric id="ID_4" name="dei:EntityFileNumber" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657">333-261063</ix:nonNumeric></div><div id="a66" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:616px;top:410px;"><ix:nonNumeric id="ID_5" name="dei:EntityTaxIdentificationNumber" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657">86-2083865</ix:nonNumeric></div><div id="a70" style="position:absolute;font-family:'Times New Roman';left:98px;top:426px;">(State or other jurisdiction</div><div id="a72" style="position:absolute;font-family:'Times New Roman';left:372px;top:426px;">(Commission</div><div id="a74" style="position:absolute;font-family:'Times New Roman';left:607px;top:426px;">(IRS Employer</div><div id="a76" style="position:absolute;font-family:'Times New Roman';left:123px;top:441px;">of incorporation)</div><div id="a78" style="position:absolute;font-family:'Times New Roman';left:372px;top:441px;">File Number)</div><div id="a80" style="position:absolute;font-family:'Times New Roman';left:598px;top:441px;">Identification No.)</div><div id="a91" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:346px;top:487px;"><ix:nonNumeric id="ID_6" name="dei:EntityAddressAddressLine1" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657">1717 Main St</ix:nonNumeric></div><div id="a91_12_2" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:422px;top:487px;">, </div><div id="a91_14_7" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:429px;top:487px;"><ix:nonNumeric id="ID_7" name="dei:EntityAddressAddressLine2" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657">Ste 338</ix:nonNumeric></div><div id="a93" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:358px;top:502px;"><ix:nonNumeric id="ID_8" name="dei:EntityAddressCityOrTown" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657">Dallas</ix:nonNumeric></div><div id="a93_6_2" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:393px;top:502px;">, </div><div id="a93_8_2" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:400px;top:502px;"><ix:nonNumeric id="ID_9" name="dei:EntityAddressStateOrProvince" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657">TX</ix:nonNumeric></div><div id="a93_10_2" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:418px;top:502px;">, </div><div id="a93_12_5" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:425px;top:502px;"><ix:nonNumeric id="ID_10" name="dei:EntityAddressPostalZipCode" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657">75201</ix:nonNumeric></div><div id="a95" style="position:absolute;font-family:'Times New Roman';left:271px;top:518px;">(Address of principal executive offices) (Zip Code) </div><div id="a105" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:215px;top:548px;">Registrant&#8217;s telephone number,<div style="display:inline-block;width:6px">&#160;</div>including area code: (</div><div id="a105_53_3" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:522px;top:548px;"><ix:nonNumeric id="ID_11" name="dei:CityAreaCode" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657">254</ix:nonNumeric></div><div id="a105_56_2" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:542px;top:548px;">) </div><div id="a105_58_8" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:550px;top:548px;"><ix:nonNumeric id="ID_12" name="dei:LocalPhoneNumber" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657">244-5739</ix:nonNumeric></div><div id="a112" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:367px;top:579px;">Not applicable</div><div id="a116" style="position:absolute;font-family:'Times New Roman';left:244px;top:594px;">(Former name or former address, if changed since last report)</div><div id="a120" style="position:absolute;font-family:'Times New Roman';left:288px;top:610px;">____________________________________</div><div id="a124" style="position:absolute;font-family:'Times New Roman';left:48px;top:640px;">Check the appropriate box below if the Form 8-K filing is intended<div style="display:inline-block;width:5px">&#160;</div>to simultaneously satisfy the filing obligation of the registrant </div><div id="a127" style="position:absolute;font-family:'Times New Roman';left:48px;top:656px;">under any of the following provisions:</div><div id="a131" style="position:absolute;font-family:'Segoe UI Symbol';left:48px;top:686px;"><ix:nonNumeric id="ID_13" name="dei:WrittenCommunications" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div><div id="a132" style="position:absolute;font-family:'Times New Roman';left:60px;top:688px;"><div style="display:inline-block;width:7px">&#160;</div>Written communications pursuant to Rule 425<div style="display:inline-block;width:5px">&#160;</div>under the Securities Act (17 CFR 230.425) </div><div id="a137" style="position:absolute;font-family:'Segoe UI Symbol';left:48px;top:704px;"><ix:nonNumeric id="ID_14" name="dei:SolicitingMaterial" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div><div id="a138" style="position:absolute;font-family:'Times New Roman';left:60px;top:706px;"><div style="display:inline-block;width:7px">&#160;</div>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </div><div id="a145" style="position:absolute;font-family:'Segoe UI Symbol';left:48px;top:721px;"><ix:nonNumeric id="ID_15" name="dei:PreCommencementTenderOffer" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div><div id="a146" style="position:absolute;font-family:'Times New Roman';left:60px;top:724px;"><div style="display:inline-block;width:7px">&#160;</div>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange<div style="display:inline-block;width:5px">&#160;</div>Act (17 CFR 240.14d-2(b)) </div><div id="a157" style="position:absolute;font-family:'Segoe UI Symbol';left:48px;top:739px;"><ix:nonNumeric id="ID_16" name="dei:PreCommencementIssuerTenderOffer" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div><div id="a158" style="position:absolute;font-family:'Times New Roman';left:60px;top:741px;"><div style="display:inline-block;width:7px">&#160;</div>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange<div style="display:inline-block;width:5px">&#160;</div>Act (17 CFR 240.13e-4(c)) </div><div id="a167" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:48px;top:757px;"><div style="display:inline-block;width:3px">&#160;</div></div><div id="a169" style="position:absolute;font-family:'Times New Roman';left:48px;top:772px;">Securities registered pursuant to Section 12(b) of the Act: </div><div id="a173" style="position:absolute;font-family:'Times New Roman';font-size:10.72px;font-weight:bold;left:130px;top:801px;">Title of each class </div><div id="a176" style="position:absolute;font-family:'Times New Roman';font-size:10.72px;font-weight:bold;left:397px;top:789px;">Trading </div><div id="a178" style="position:absolute;font-family:'Times New Roman';font-size:10.72px;font-weight:bold;left:392px;top:801px;">Symbol(s) </div><div id="a181" style="position:absolute;font-family:'Times New Roman';font-size:10.72px;font-weight:bold;left:600px;top:789px;">Name of each exchange </div><div id="a183" style="position:absolute;font-family:'Times New Roman';font-size:10.72px;font-weight:bold;left:608px;top:801px;">on which registered </div><div id="a185" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:50px;top:817px;"><ix:nonNumeric id="ID_18" name="dei:Security12bTitle" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657" continuedAt="XBRL_CS_554ec84c04af4e189c964f216a94b90c_1">Class A Common Stock, par value $0.0001 </ix:nonNumeric></div><div id="a191" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:144px;top:832px;"><ix:continuation id="XBRL_CS_554ec84c04af4e189c964f216a94b90c_1">per share</ix:continuation></div><div id="a194" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:396px;top:817px;"><ix:nonNumeric id="ID_19" name="dei:TradingSymbol" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657">VAXX</ix:nonNumeric></div><div id="a197" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:574px;top:817px;">The </div><div id="a197_4_6" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:600px;top:817px;-sec-ix-hidden:ID_20;">Nasdaq</div><div id="a197_10_16" style="position:absolute;font-family:'Times New Roman';font-weight:bold;left:643px;top:817px;"><div style="display:inline-block;width:3px">&#160;</div>Global Market<div style="display:inline-block;width:4px">&#160;</div></div><div id="a202" style="position:absolute;font-family:'Times New Roman';left:48px;top:863px;">Indicate by check mark whether the registrant is an emerging growth<div style="display:inline-block;width:5px">&#160;</div>company as defined in Rule 405 of the Securities Act of 1933 </div><div id="a204" style="position:absolute;font-family:'Times New Roman';left:48px;top:878px;">(&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of<div style="display:inline-block;width:5px">&#160;</div>1934 (&#167;240.12b-2 of this chapter). </div><div id="a213" style="position:absolute;font-family:'Times New Roman';left:48px;top:911px;">Emerging growth company<div style="display:inline-block;width:4px">&#160;</div></div><div id="a216" style="position:absolute;font-family:'Segoe UI Symbol';left:201px;top:909px;"><ix:nonNumeric id="ID_21" name="dei:EntityEmergingGrowthCompany" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></div><div id="a219" style="position:absolute;font-family:'Times New Roman';left:48px;top:942px;">If an emerging growth company,<div style="display:inline-block;width:5px">&#160;</div>indicate by check mark if the registrant has elected not to use the extended transition period<div style="display:inline-block;width:5px">&#160;</div>for </div><div id="a222" style="position:absolute;font-family:'Times New Roman';left:48px;top:959px;">complying with any new or revised financial accounting standards provided<div style="display:inline-block;width:5px">&#160;</div>pursuant to Section 13(a) of the Exchange<div style="display:inline-block;width:4px">&#160;</div>Act.<div style="display:inline-block;width:3px">&#160;</div></div><div id="a225" style="position:absolute;font-family:'Segoe UI Symbol';left:713px;top:957px;"><ix:nonNumeric id="ID_17" name="dei:EntityExTransitionPeriod" contextRef="FROM_Mar24_2022_TO_Mar24_2022_Entity_0001851657" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div></div>
</div>
<div style="padding: 7px">
<div id="Page2" style="background-color:RGB(255, 255, 255);position:relative;margin-left:auto;margin-right:auto;overflow:hidden;border-style:solid;border-width:thin;border-color:RGB(198, 198, 198);page-break-after:always;width:816px;height:1056px;">
<div style="position:absolute; width:71.9px; height:1.4px; left:48px; top:237.8px; background-color:#000000; ">&#160;</div>
<div style="position:absolute; width:72.3px; height:1.4px; left:156.5px; top:237.8px; background-color:#000000; ">&#160;</div>
<div id="a228" style="position:absolute;font-family:'Times New Roman';font-size:16px;font-weight:bold;left:96px;top:48px;">Item 2.02 Results of Operations and Financial Condition.<div style="display:inline-block;width:4px">&#160;</div></div><div id="a230" style="position:absolute;font-family:'Times New Roman';font-size:16px;left:48px;top:83px;">On March 24, 2022, Vaxxinity,<div style="display:inline-block;width:7px">&#160;</div>Inc. (the &#8220;Company&#8221;) issued a press release announcing its operating and </div><div id="a231" style="position:absolute;font-family:'Times New Roman';font-size:16px;left:48px;top:101px;">financial results for the fourth quarter and year ended December 31, 2021. A copy of the press release is </div><div id="a233" style="position:absolute;font-family:'Times New Roman';font-size:16px;left:48px;top:120px;">furnished as Exhibit 99.1 to this report and incorporated herein by reference. </div><div id="a235" style="position:absolute;font-family:'Times New Roman';font-size:16px;font-weight:bold;left:48px;top:154px;">Item 9.01. Financial Statements and Exhibits.<div style="display:inline-block;width:4px">&#160;</div></div><div id="a237" style="position:absolute;font-family:'Times New Roman';font-size:16px;left:96px;top:188px;">(d) Exhibits </div><div id="a239" style="position:absolute;font-family:'Times New Roman';font-size:14.72px;font-weight:bold;left:48px;top:223px;">Exhibit No.<div style="display:inline-block;width:37px">&#160;</div>Description </div><div id="a245" style="position:absolute;font-family:'Times New Roman';font-size:16px;color:#0000FF;left:48px;top:256px;"><a href="exhibit991.htm" style="color:#0000FF;text-decoration:underline;">99.1</a></div><div id="a247" style="position:absolute;font-family:'Times New Roman';font-size:16px;color:#0000FF;left:158px;top:256px;"><a href="exhibit991.htm" style="color:#0000FF;text-decoration:underline;">Press Release issued by Vaxxinity,<span style="display:inline-block;width:7px;text-decoration:underline">&#160;</span>Inc. on March 24, 2022</a></div><div id="a249" style="position:absolute;font-family:'Times New Roman';font-size:16px;left:48px;top:290px;">104 </div><div id="a251" style="position:absolute;font-family:'Times New Roman';font-size:16px;left:158px;top:290px;">Cover Page Interactive Data File (embedded within the Inline XBRL document). </div><div id="a253" style="position:absolute;font-family:'Times New Roman';font-size:16px;font-weight:bold;left:408px;top:324px;"><div style="display:inline-block;width:192px">&#160;</div></div></div>
</div>
<div style="padding: 7px">
<div id="Page3" style="background-color:RGB(255, 255, 255);position:relative;margin-left:auto;margin-right:auto;overflow:hidden;border-style:solid;border-width:thin;border-color:RGB(198, 198, 198);page-break-after:always;width:816px;height:1056px;">
<div style="position:absolute; width:263.7px; height:1px; left:503.1px; top:253.4px; background-color:#000000; ">&#160;</div>
<div id="a256" style="position:absolute;font-family:'Times New Roman';font-size:16px;font-weight:bold;left:356px;top:48px;">SIGNATURES </div><div id="a258" style="position:absolute;font-family:'Times New Roman';font-size:16px;left:96px;top:83px;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this </div><div id="a260" style="position:absolute;font-family:'Times New Roman';font-size:16px;left:48px;top:101px;">report to be signed on its behalf by the undersigned hereunto duly authorized. </div><div id="a262" style="position:absolute;font-family:'Times New Roman';font-size:16px;left:384px;top:136px;">Vaxxinity,<div style="display:inline-block;width:7px">&#160;</div>Inc.<div style="display:inline-block;width:4px">&#160;</div></div><div id="a272" style="position:absolute;font-family:'Times New Roman';font-size:16px;left:473px;top:236px;">By: </div><div id="a274" style="position:absolute;font-family:'Times New Roman';font-size:16px;left:517px;top:236px;">/s/ Ren&#233; Paula </div><div id="a281" style="position:absolute;font-family:'Times New Roman';font-size:16px;left:510px;top:255px;">Name: </div><div id="a283" style="position:absolute;font-family:'Times New Roman';font-size:16px;left:570px;top:255px;">Ren&#233; Paula </div><div id="a289" style="position:absolute;font-family:'Times New Roman';font-size:16px;left:510px;top:273px;">Title: </div><div id="a291" style="position:absolute;font-family:'Times New Roman';font-size:16px;left:570px;top:273px;">General Counsel and </div><div id="a292" style="position:absolute;font-family:'Times New Roman';font-size:16px;left:570px;top:292px;">Secretary </div><div id="a264" style="position:absolute;font-family:'Times New Roman';font-size:16px;left:48px;top:168px;">Date: March 28, 2022 </div></div>
</div>
</div>
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "20220317_8k.htm", "secsgml_size_bytes": 23253}]
{"company-data": {"conformed-name": "Vaxxinity, Inc.", "cik": "0001851657", "assigned-sic": "2834", "irs-number": "862083865", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-41058", "film-number": "22775340"}, "business-address": {"street1": "1717 MAIN STREET", "street2": "SUITE 3388", "city": "DALLAS", "state": "TX", "zip": "75201", "phone": "(254) 244-5739"}, "mail-address": {"street1": "1717 MAIN STREET", "street2": "SUITE 3388", "city": "DALLAS", "state": "TX", "zip": "75201"}}
20220317_8k
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________
FORM
8-K
____________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
March 24, 2022
____________________________________
Vaxxinity, Inc.
(Exact name of registrant as specified in its charter)
____________________________________
Delaware
333-261063
86-2083865
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)
1717 Main St
,
Ste 338
Dallas
,
TX
,
75201
(Address of principal executive offices) (Zip Code)
Registrant's telephone number,
including area code: (
254
)
244-5739
Not applicable
(Former name or former address, if changed since last report)
____________________________________
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Class A Common Stock, par value $0.0001
per share
VAXX
The
Nasdaq
Global Market
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period
for
complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act.
☐
Item 2.02 Results of Operations and Financial Condition.
On March 24, 2022, Vaxxinity,
Inc. (the "Company") issued a press release announcing its operating and
financial results for the fourth quarter and year ended December 31, 2021. A copy of the press release is
furnished as Exhibit 99.1 to this report and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release issued by Vaxxinity,
Inc. on March 24, 2022
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
Vaxxinity,
Inc.
By:
/s/ René Paula
Name:
René Paula
Title:
General Counsel and
Secretary
Date: March 28, 2022